AR036086A1 - Compuestos de {[ 2- morfonil-4-il]-2-oxoetil}-(2-oxopirrolidinil 3-il)naftalen-2-sulfonamida, composiciones farmaceuticas formuladas con dichos compuestos; uso de dichos compuestos en la manufactura de medicamentos para el tratamiento de condiciones susceptibles de mejoramiento mediante la inhibicio - Google Patents
Compuestos de {[ 2- morfonil-4-il]-2-oxoetil}-(2-oxopirrolidinil 3-il)naftalen-2-sulfonamida, composiciones farmaceuticas formuladas con dichos compuestos; uso de dichos compuestos en la manufactura de medicamentos para el tratamiento de condiciones susceptibles de mejoramiento mediante la inhibicioInfo
- Publication number
- AR036086A1 AR036086A1 ARP020102128A ARP020102128A AR036086A1 AR 036086 A1 AR036086 A1 AR 036086A1 AR P020102128 A ARP020102128 A AR P020102128A AR P020102128 A ARP020102128 A AR P020102128A AR 036086 A1 AR036086 A1 AR 036086A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- compounds
- group
- 3alkyl
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se describen y reivindican compuestos que posee propiedades inhibitorias del factor Xa de fórmula (1) donde R1 representa hidrógeno, -alquilo C1-6, alquenilo C3-6, -(alquil C2-3)NRbRc, -(alquil C2-3)NHCORb, fenilo o un grupo heterocíclico aromático de 5 o 6 miembros, estando el fenilo o el grupo heterocíclico aromático de 5 o 6 miembros opcionalmente sustituidos con halógeno, o R1 representa un grupo X-W, en el que X representa alquileno C1-3 y W representa -CN, -CO2H, -CONRbRc, -COalquilo C1-6, -CO2alquilo C1-6, fenilo o un grupo heterocíclico aromático o no aromático de 5 o 6 miembros que contiene al menos un heteroátomo seleccionado entre O, N o S, estando el fenilo o el grupo heterocíclico aromático opcionalmente sustituido con uno o más sustituyentes seleccionados entre: alquilo C1-3, -alcoxi C1-3, (alquil C1-3)OH, halógeno, -CN, -CF3, NH2, -CO2H y -OH; R2 y R3 representan independientemente hidrógeno, -alquilo C1-3 o -CF3 con la condición de que uno de R2 y R3 es alquilo- C1-3 o CF3 y el otro es hidrógeno; Rb y Rc representan independientemente hidrógeno o -alquilo C1-3; A representa un grupo seleccionado entre: el grupo de fórmulas (2); Z representa uno o dos sustituyentes opcionales seleccionados independientemente entre halógeno y OH, W representa un sustituyente opcional -alquilo C1-3, Alq representa alquileno C2-3 o alquenileno C2-3, T representa un heteroátomo seleccionado entre O, N o S; B representa uno o más sustituyentes opcionales sobre los átomos de carbono del anillo seleccionados entre (1) uno o más sustituyentes seleccionados entre -CF3, -F, -CO2H, -alquilo C1-6, -(alquil C1-6)OH, -(alquil C1-3)NRbRc y -(alquil C0-3)CONRbRc y -(alquil C0-3) CO2alquiloC1-3, -CONH(alquil C2-3)OH, -CH2NH(alquil C2-3)OH, -CH2Oalquilo C1-3 y -CH2SO2alquilo C1-3; (2) un grupo -Y -Re, Y representa -alquileno C1-3-, -CO-, -(alquil C1-3)NH-, -(alquil C1-3)NHCO-, -(alquil C1-3)NHSO2-, -CH2NHSO2CH2- o un enlace directo, Re representa fenilo, un cicloalquilo de 5 a 6i miembros o un heterociclo de 5 o 6 miembros que contiene al menos un heteroátomo seleccionado entre O, N o S, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados entre: -alquilo C1-3, -alcoxi C1-3, -(alquil C1-3)OH, halógeno, -CN, CF3, -NH2, -CO2H y -OH, o (3) un segundo anillo R1 que está condensado con el anillo heterocíclico en el que R1 representa fenilo, un grupo cicloalquilo de 5 o 6 miembros o un grupo heterocíclico aromático de 5 o 6 miembros que contiene al menos un heteroátomo seleccionado entre O, N o S, y el grupo bicíclico condensado está opcionalmente sustituido con uno o más sustituyentes seleccionados entre: -alquilo C1-3, -alcoxi C1-3, -(alquil C1-3)OH, halógeno, -CN, -CF3, -NH2, -CO2H y -OH, y sus derivados farmacéuticamente aceptables. Se describen y reivindican los objetos restantes mencionados en el título.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0114005.2A GB0114005D0 (en) | 2001-06-08 | 2001-06-08 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036086A1 true AR036086A1 (es) | 2004-08-11 |
Family
ID=9916209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102128A AR036086A1 (es) | 2001-06-08 | 2002-06-06 | Compuestos de {[ 2- morfonil-4-il]-2-oxoetil}-(2-oxopirrolidinil 3-il)naftalen-2-sulfonamida, composiciones farmaceuticas formuladas con dichos compuestos; uso de dichos compuestos en la manufactura de medicamentos para el tratamiento de condiciones susceptibles de mejoramiento mediante la inhibicio |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US7186717B2 (es) |
| EP (1) | EP1395553B1 (es) |
| JP (1) | JP4242274B2 (es) |
| KR (1) | KR100877245B1 (es) |
| CN (1) | CN1256324C (es) |
| AR (1) | AR036086A1 (es) |
| AT (1) | ATE289294T1 (es) |
| AU (1) | AU2002311451B2 (es) |
| BR (1) | BR0210207A (es) |
| CA (1) | CA2449629A1 (es) |
| CO (1) | CO5540285A2 (es) |
| CZ (1) | CZ20033325A3 (es) |
| DE (1) | DE60203006T2 (es) |
| DK (1) | DK1395553T3 (es) |
| ES (1) | ES2235050T3 (es) |
| GB (1) | GB0114005D0 (es) |
| HK (1) | HK1063471A1 (es) |
| HU (1) | HUP0400156A3 (es) |
| IL (1) | IL159195A0 (es) |
| MX (1) | MXPA03011384A (es) |
| MY (1) | MY136859A (es) |
| NO (1) | NO326689B1 (es) |
| NZ (1) | NZ530004A (es) |
| PL (1) | PL368082A1 (es) |
| PT (1) | PT1395553E (es) |
| SI (1) | SI1395553T1 (es) |
| TW (1) | TWI298719B (es) |
| WO (1) | WO2002100830A1 (es) |
| ZA (1) | ZA200309367B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0114005D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0130705D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Chemical compounds |
| GB0228533D0 (en) | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Crystalline form |
| GB0228552D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Chemical compounds |
| US20050119266A1 (en) * | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
| EP1637141B1 (en) * | 2004-09-21 | 2011-11-16 | Trobio AB | Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease |
| AU2005299693B2 (en) * | 2004-10-26 | 2012-07-05 | Janssen Pharmaceutica, N.V. | Factor Xa compounds |
| WO2006110726A2 (en) * | 2005-04-11 | 2006-10-19 | Glaxo Group Limited | Dosage formulations and methods of treatment and prevention |
| AU2005336535B2 (en) * | 2005-09-22 | 2012-05-24 | Trobio Ab | Stabilized protease composition |
| CN102380100A (zh) * | 2005-09-22 | 2012-03-21 | 特罗比奥股份公司 | 稳定的蛋白酶组合物 |
| DE102007028407A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028319A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028406A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| CN105143213B (zh) * | 2013-04-26 | 2018-07-24 | 赛诺菲 | 5-氯-噻吩-2-甲酸[(s)-2-[甲基-3-(2-氧代-吡咯烷-1-基)-苯磺酰基氨基]-3-(4-甲基-哌嗪-1-基)-3-氧代-丙基]酰胺的酒石酸盐 |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| EP3078378B1 (en) | 2015-04-08 | 2020-06-24 | Vaiomer | Use of factor xa inhibitors for regulating glycemia |
| EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92011A0 (en) | 1988-10-19 | 1990-07-12 | Abbott Lab | Heterocyclic peptide renin inhibitors |
| DE4035961A1 (de) * | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE4121947A1 (de) | 1991-07-03 | 1993-01-07 | Basf Ag | 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung |
| US5703208A (en) | 1994-06-17 | 1997-12-30 | Corvas International, Inc. | 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors |
| JP2001504810A (ja) | 1996-10-11 | 2001-04-10 | シーオーアール・セラピューティックス・インコーポレーテッド | 選択的第Ｘａ因子阻害剤 |
| US6281227B1 (en) | 1996-12-13 | 2001-08-28 | Aventis Pharma Deutschland Gmbh | Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
| ES2184145T3 (es) | 1996-12-13 | 2003-04-01 | Aventis Pharma Inc | Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida. |
| US6602864B1 (en) | 1996-12-13 | 2003-08-05 | Aventis Pharma Deutschland Gmbh | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds |
| US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| IL123986A (en) | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
| ID23991A (id) * | 1997-09-30 | 2000-06-14 | Daiichi Seiyaku Co | Turunan-turunan sulfonil |
| UA59433C2 (uk) | 1998-01-27 | 2003-09-15 | Авентіс Фармасьютікалс Продактс Інк. | ЗАМІЩЕНІ ОКСОАЗАГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ ФАКТОРА Хa ТА ПРОМІЖНІ СПОЛУКИ ДЛЯ ЇХ ОТРИМАННЯ |
| US6281277B1 (en) | 1998-04-22 | 2001-08-28 | Showa Denko Kabushiki Kaisha | Homogeneously surface-fluorinated metal oxide particulates, process for manufacturing the same, and use of the same |
| EP1150976B1 (en) | 1998-12-31 | 2003-02-26 | Aventis Pharmaceuticals Inc. | 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| JP2002536437A (ja) | 1999-02-09 | 2002-10-29 | ブリストル−マイヤーズ スクイブ カンパニー | ＦＸａのラクタム抑制剤および方法 |
| WO2000055188A1 (fr) * | 1999-03-16 | 2000-09-21 | C & C Research Laboratories | Derives de proline substitues et compositions medicinales les contenant |
| WO2000069465A1 (fr) | 1999-05-12 | 2000-11-23 | Ono Pharmaceutical Co., Ltd. | Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif |
| IL147495A0 (en) | 1999-07-28 | 2002-08-14 | Aventis Pharm Prod Inc | Substituted oxoazaheterocycclyl compounds |
| JP2004518688A (ja) | 2001-01-30 | 2004-06-24 | ブリストル−マイヤーズ スクイブ カンパニー | ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法 |
| GB0114004D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0114005D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0228552D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Chemical compounds |
| GB0228533D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Crystalline form |
-
2001
- 2001-06-08 GB GBGB0114005.2A patent/GB0114005D0/en not_active Ceased
-
2002
- 2002-06-06 JP JP2003503599A patent/JP4242274B2/ja not_active Expired - Fee Related
- 2002-06-06 PL PL02368082A patent/PL368082A1/xx unknown
- 2002-06-06 PT PT02738368T patent/PT1395553E/pt unknown
- 2002-06-06 NZ NZ530004A patent/NZ530004A/en unknown
- 2002-06-06 CN CNB028154002A patent/CN1256324C/zh not_active Expired - Fee Related
- 2002-06-06 HU HU0400156A patent/HUP0400156A3/hu unknown
- 2002-06-06 EP EP02738368A patent/EP1395553B1/en not_active Expired - Lifetime
- 2002-06-06 ES ES02738368T patent/ES2235050T3/es not_active Expired - Lifetime
- 2002-06-06 AR ARP020102128A patent/AR036086A1/es unknown
- 2002-06-06 CA CA002449629A patent/CA2449629A1/en not_active Abandoned
- 2002-06-06 TW TW091112153A patent/TWI298719B/zh active
- 2002-06-06 US US10/479,545 patent/US7186717B2/en not_active Expired - Fee Related
- 2002-06-06 IL IL15919502A patent/IL159195A0/xx unknown
- 2002-06-06 DE DE60203006T patent/DE60203006T2/de not_active Expired - Lifetime
- 2002-06-06 MX MXPA03011384A patent/MXPA03011384A/es active IP Right Grant
- 2002-06-06 SI SI200230101T patent/SI1395553T1/xx unknown
- 2002-06-06 BR BR0210207-2A patent/BR0210207A/pt not_active Application Discontinuation
- 2002-06-06 DK DK02738368T patent/DK1395553T3/da active
- 2002-06-06 MY MYPI20022097A patent/MY136859A/en unknown
- 2002-06-06 AU AU2002311451A patent/AU2002311451B2/en not_active Ceased
- 2002-06-06 WO PCT/GB2002/002721 patent/WO2002100830A1/en active IP Right Grant
- 2002-06-06 AT AT02738368T patent/ATE289294T1/de not_active IP Right Cessation
- 2002-06-06 KR KR1020037016070A patent/KR100877245B1/ko not_active IP Right Cessation
- 2002-06-06 CZ CZ20033325A patent/CZ20033325A3/cs unknown
-
2003
- 2003-12-02 ZA ZA200309367A patent/ZA200309367B/en unknown
- 2003-12-05 NO NO20035440A patent/NO326689B1/no not_active IP Right Cessation
- 2003-12-05 CO CO03107408A patent/CO5540285A2/es not_active Application Discontinuation
-
2004
- 2004-08-23 HK HK04106291A patent/HK1063471A1/xx not_active IP Right Cessation
-
2006
- 2006-10-11 US US11/548,402 patent/US7517879B2/en not_active Expired - Fee Related
- 2006-10-11 US US11/548,395 patent/US7429587B2/en not_active Expired - Fee Related
- 2006-10-11 US US11/548,404 patent/US7326785B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036086A1 (es) | Compuestos de {[ 2- morfonil-4-il]-2-oxoetil}-(2-oxopirrolidinil 3-il)naftalen-2-sulfonamida, composiciones farmaceuticas formuladas con dichos compuestos; uso de dichos compuestos en la manufactura de medicamentos para el tratamiento de condiciones susceptibles de mejoramiento mediante la inhibicio | |
| AR071799A1 (es) | Derivados de hexafluoroisopropanol | |
| AR018175A1 (es) | Compuestos de indol-3-glioxilamidas sustituidas, utiles como medicamentos antitumorales, composiciones farmaceuticas formuladas con dichos derivados,utilizacion de dichos derivados para la preparacion de medicamentos antitumorales y los medicamentos asi preparados. | |
| AR033306A1 (es) | Compuestos | |
| AR002746A1 (es) | Compuestos derivados de pirimidina condensados con un anillo heterociclico y composicion farmaceutica conteniendo dichos compuestos. | |
| AR035260A1 (es) | Derivados de piperidina amino sustituidas, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de medicamentos como inhibidores de la gama secretasa, y para el tratamiento de la enfermedad de alzheimer | |
| AR072969A1 (es) | Derivados de ciclohexilamida, composiciones farmaceuticas y usos como antagonistas del receptor del factor de liberacion de corticotropina (crf - 1) | |
| AR034390A1 (es) | Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa | |
| DE60318030D1 (de) | Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| HUP0402508A2 (hu) | 1,2,3,4-Tetrahidro-izokinolin-származékok mint urotenzin II receptor antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények | |
| BRPI0414450A (pt) | derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
| DE69231395T2 (de) | Neue medizinische Indikation für Tachykinin-Antagonisten | |
| AR007077A1 (es) | Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento | |
| AR022283A1 (es) | Aminas substituidas de espirofuropiridinas novedosas utiles en terapia | |
| AR070992A1 (es) | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 | |
| YU48854B (sh) | Derivati n-(4-piperidinil) (dihidrobenzofuran ili dihidro-2h-benzopiran)karboksamida i postupak za njihovo dobijanje | |
| AR052824A1 (es) | Derivados de eritromicina | |
| AR009938A1 (es) | Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos | |
| AR062405A1 (es) | Derivados de isoindol | |
| AR048501A1 (es) | Compuesto de benzoazabicicloheptano dimerico, composicion farmaceutica que lo comprende y su uso para prepararla | |
| AR027744A1 (es) | Compuestos de eter difenilico utiles en terapia | |
| AR046793A1 (es) | Derivados de pirazol, antagonistas del receptor de la orexina | |
| AR012622A1 (es) | Inhibidores de proteasas, procedimiento para su preparacion, composicion farmaceutica que los comprende y el uso de los mismos en la fabricacion de unmedicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |